Provided by Tiger Trade Technology Pte. Ltd.

Argenx SE

984.99
-17.3200-1.73%
Volume:160.46K
Turnover:159.40M
Market Cap:61.60B
PE:37.58
High:1,000.18
Open:991.05
Low:982.31
Close:1,002.31
52wk High:1,072.75
52wk Low:661.85
Shares:62.54M
Float Shares:62.45M
Volume Ratio:0.90
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):26.21
EPS(LYR):19.57
ROE:23.63%
ROA:11.63%
PB:7.32
PE(LYR):50.33

Loading ...

Movement Alert|Argenx SE Declines 3.83% Overnight, Trading at $950.02

Market Focus
·
Aug 18

Argenx Se (ARGX) Receives a Buy from Citi

TIPRANKS
·
Aug 18

Argenx Se : TD Cowen Raises Target Price to $1353 from $1146

THOMSON REUTERS
·
Aug 18

Argenx Se : Truist Securities Raises Target Price to $1095 from $1030

THOMSON REUTERS
·
Aug 18

ADRs Close Higher; Argenx SE Climbs 16%

Dow Jones
·
Aug 18

William Blair says Argenx’s ALKIVIA results boost confidence in Vyvgart DM path

TIPRANKS
·
Aug 18

Argenx Stock Heads for Record After Blockbuster Drug Delivers Another Win

Dow Jones
·
Aug 18

argenx SE Stock (ARGX) Moved Up by 16.67% on Aug 17: Drivers Behind the Movement

TradingKey
·
Aug 18

Argenx Price Target Raised to $1215.00/Share from $1075.00 by Piper Sandler

Dow Jones
·
Aug 18

European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading

MT Newswires Live
·
Aug 17

Wedbush Adjusts Argenx PT to $1,150 From $1,050, Maintains Outperform Rating

MT Newswires Live
·
Aug 17

Argenx SE (ARGX) Stock Soars 15% on Positive Phase 3 Study Results

TIPRANKS
·
Aug 17

Argenx SE up over 15%, on Pace for Largest Percent Increase Since July 2023

Dow Jones
·
Aug 17

Argenx rises 14.9%

TIPRANKS
·
Aug 17

Movement Alert|Argenx SE Rises 9.45% in Regular Trading, Phase 3 Trial of Efgartigimod in Autoimmune Myositis Meets Primary Endpoint

Market Focus
·
Aug 17

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Lower Rate Hike Expectations

MT Newswires Live
·
Aug 17

Sector Update: Healthcare

MT Newswires Live
·
Aug 17

Argenx price target raised to $1,215 from $1,075 at Piper Sandler

TIPRANKS
·
Aug 17

Movement Alert|Argenx SE Rises 5% in Pre-Market Trading, Phase 3 Trial of Efgartigimod in Autoimmune Myositis Meets Primary Endpoint

Market Focus
·
Aug 17

argenx Says Autoimmune Myositis Drug Meets Main Goal in Phase 3 Study

MT Newswires Live
·
Aug 17